|
1
|
Filho AM, Laversanne M, Ferlay J, Colombet
M, Piñeros M, Znaor A, Parkin DM, Soerjomataram I and Bray F: The
GLOBOCAN 2022 cancer estimates: Data sources, methods, and a
snapshot of the cancer burden worldwide. Int J Cancer.
156:1336–1346. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal J: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
3
|
Wang LB, Zhao JF, Cao J, Tao X, Wang J, Ma
JR, Huang Q, Yu JJ, Tian JH and Zhang QH: Integrative analysis of
differentially expressed mRNAs and proteins induced by PGC-1β in
breast cancer cells. Biochem Biophys Res Commun. 637:73–82. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang YZ, Ma D, Suo C, Shi JX, Xue MZ, Hu
X, Xiao Y, Yu KD, Liu YR, YU Y, et al: Genomic and transcriptomic
landscape of triple-negative breast cancers: Subtypes and treatment
strategies. Cancer Cell. 35:428–440.e5. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Muriithi W, Macharia LW, Heming CP,
Echevarria JL, Nyachieo A, Filho PN and Neto VM: ABC transporters
and the hallmarks of cancer: Roles in cancer aggressiveness beyond
multidrug resistance. Cancer Biol Med. 17:253–269. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dean M, Rzhetsky A and Allikmets R: The
human ATP-binding cassette (ABC) transporter superfamily. Genome
Res. 42:1156–1166. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu X: ABC family transporters. Adv Exp
Med Biol. 1141:13–100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goda K, Bacsó Z and Szabó G: Multidrug
resistance through the spectacle of P-glycoprotein. Curr Cancer
Drug Targets. 9:281–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wegler C, Gazit M, Issa K, Subramaniam S,
Artursson P and Karlgren M: Expanding the efflux in vitro assay
toolbox: A CRISPR-Cas9 edited MDCK cell line with human BCRP and
completely lacking canine MDR1. J Pharm Sci. 110:388–396. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Almohammad Aljabr B, Zihlif M, Abu-Dahab R
and Zalloum H: Effect of quercetin on doxorubicin cytotoxicity in
sensitive and resistant human MCF7 breast cancer cell lines. Biomed
Rep. 20:582024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang H, Kuang Y, Wu W, Peng B and Fu Q:
Quercetin inhibits the metabolism of arachidonic acid by inhibiting
the activity of CYP3A4, thereby inhibiting the progression of
breast cancer. Mol Med. 29:1272023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Safi A, Heidarian E and Ahmadi R:
Quercetin synergistically enhances the anticancer efficacy of
docetaxel through induction of apoptosis and modulation of
PI3K/AKT, MAPK/ERK, and JAK/STAT3 signaling pathways in MDA-MB-231
breast cancer cell line. Int J Mol Cell Med. 10:11–22.
2021.PubMed/NCBI
|
|
13
|
Kıyga E, Şengelen A, Adıgüzel Z and Önay
Uçar E: Investigation of the role of quercetin as a heat shock
protein inhibitor on apoptosis in human breast cancer cells. Mol
Biol Rep. 47:4957–4967. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thies KA, Lefler JE, Leone G and Ostrowski
MC: PTEN in the Stroma. Cold Spring Harb Perspect Med.
9:a0361112019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lefler JE, Seward C and Ostrowski MC: PTEN
in cancer associated fibroblasts. Adv Cancer Res. 154:203–226.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bhave MA, Quintanilha JCF, Tukachinsky H,
Li G, Scott T, Ross JS, Pasquina L, Huang RSP, McArthur H, Levy MA,
et al: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and
PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along
treatment course and predictive value for endocrine therapy
resistance in real-world practice. Breast Cancer Res Treat.
207:599–609. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ngeow J, Stanuch K, Mester JL,
Barnholtz-Sloan JS and Eng C: Second malignant neoplasms in
patients with Cowden syndrome with underlying germline PTEN
mutations. J Clin Oncol. 32:1818–1824. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Molina-Montes E, Requena M,
Sánchez-Cantalejo E, Fernández MF, Arroyo-Morales M, Espín J,
Arrebola JP and Sánchez MJ: Risk of second cancers cancer after a
first primary breast cancer: A systematic review and meta-analysis.
Gynecol Oncol. 136:158–171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pote M and Gacche RN: ATP-binding cassette
efflux transporters and MDR in cancer. Drug Discov Today.
28:1035372023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garrido-Castro AC, Lin NU and Polyak K:
Insights into molecular classifications of triple-negative breast
cancer: Improving patient selection for treatment. Cancer Discov.
9:176–198. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gu J, Huang W, Wang X, Zhang J, Tao T,
Zheng Y, Liu S, Yang J, Chen ZS, Cai CY, et al:
Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC
transporters to reverse gemcitabine resistance in pancreatic
cancer. Mol Cancer. 21:1122022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qiu F, Chen J, Cao J, Diao F and Huang P:
Low-intensity low-frequency ultrasound enhances the
chemosensitivity of gemcitabine-resistant ASPC-1 cells via
PI3K/AKT/NF-κB pathway mediated ABC transporters. Oncol Rep.
44:1158–1168. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sui H, Pan SF, Feng Y, Jin BH, Liu X, Zhou
H, Hou FG, Wang WH, Fu XL, Han ZF, et al: Zuo Jin Wan reverses
P-gp-mediated drug-resistance by inhibiting activation of the
PI3K/Akt/NF-κB pathway. BMC Complement Altern Med. 14:2792014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dong W, Liao ZG, Zhao GW, Guan XJ, Zhang
J, Liang XL and Yang M: Reversal effect of oxypeucedanin on
P-glycoprotein-mediated drug transport. Molecules. 23:18412018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko
CW, Sridhara R, Justice R and Pazdur R: FDA drug approval summary:
Lapatinib in combination with capecitabine for previously treated
metastatic breast cancer that overexpresses HER-2. Oncologist.
13:1114–1119. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bao X, Lu S, Liow JS, Morse CL, Anderson
KB, Zoghbi SS, Innis RB and Pike VW: [¹¹C]Rhodamine-123:
Synthesis and biodistribution in rodents. Nucl Med Biol.
39:1128–1136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bronte G, Andrei Ds, Bravaccini S, Maltoni
R, Cecconetto L, Schirone A, Farolfi A, Fedeli A, Serra P, Donati
C, et al: Sorafenib for the treatment of breast cancer. Expert Opin
Pharmacother. 18:621–630. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ren MX, Deng XH, Ai F, Yuan GY and Song
HY: Effect of quercetin on the proliferation of the human ovarian
cancer cell line SKOV-3 in vitro. Exp Ther Med. 10:579–583. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang P, Henning SM, Magyar CE, Elshimali
Y, Heber D and Vadgama JV: Green tea and quercetin sensitize PC-3
xenograft prostate tumors to docetaxel chemotherapy. J Exp Clin
Cancer Res. 35:732016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kundur S, Prayag A, Selvakumar P, Nguyen
H, McKee L, Cruz C, Srinivasan A, Shoyele S and Lakshmikuttyamma A:
Synergistic anticancer action of quercetin and curcumin against
triple-negative breast cancer cell lines. J Cell Physiol.
237:11103–11118. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao X, Qin T, Mao J, Zhang J, Fan S, Lu Y,
Sun Z, Zhang Q, Song B and Li L: Correction: PTENP1/miR-20a/PTEN
axis contributes to breast cancer progression by regulating PTEN
via PI3K/AKT pathway. J Exp Clin Cancer Res. 42:2022023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qian YY, Li K, Liu QY and Liu ZS: Long
non-coding RNA PTENP1 interacts with miR-193a-3p to suppress cell
migration and invasion through the PTEN pathway in hepatocellular
carcinoma. Oncotarget. 8:107859–107869. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cretella D, Digiacomo G, Giovannetti E and
Cavazzoni A: PTEN alterations as a potential mechanism for tumor
cell escape from PD-1/PD-L1 inhibition. Cancers (Basel).
11:13182019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang FF, Zhang L, Wu DS, Yuan XY, Yu YH,
Zhao XL, Chen FP and Zeng H: PTEN regulates BCRP/ABCG2 and the side
population through the PI3K/Akt pathway in chronic myeloid
leukemia. PLoS One. 9:e882982014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Miricescu D, Balan DG, Tulin A, Stiru O,
Ivacaroiu IA, Mihai DA, Popa CC, Papacoce RL, Enyedi M, Sorin NA,
et al: PI3K/AKT/mTOR signalling pathway involvement in renal cell
carcinoma pathogenesis (review). Exp Ther Med. 21:5402021.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Choi HJ, Heo JH, Park JY, Jeong JY, Cho
HJ, Park KS, Kim SH, Moon YW, Kim JS and An HJ: A novel PI3K/mTOR
dual inhibitor, CMG002, overcomes the chemoresistance in ovarian
cancer. Gynecol Oncol. 153:135–148. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu X: Transporter-mediated drug-drug
interactions and their significance In: Drug Transporters in Drug
Disposition. Effects and Toxicity. Advances in Experimental
Medicine and Biology. Liu X and Pan G: Vol 1141. Springer;
Singapore: pp. 241–291. 2019, View Article : Google Scholar : PubMed/NCBI
|
